tofacitinib psoriatic arthritis
Selected indexed studies
- Tofacitinib in psoriatic arthritis. (Immunotherapy, 2017) [PMID:28967798]
- Tofacitinib for the treatment of psoriasis and psoriatic arthritis. (G Ital Dermatol Venereol, 2020) [PMID:32348084]
- Tofacitinib: A Review in Psoriatic Arthritis. (Drugs, 2019) [PMID:30895473]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tofacitinib for the treatment of psoriasis and psoriatic arthritis. (2020) pubmed
- Tofacitinib in psoriatic arthritis. (2017) pubmed
- Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. (2024) pubmed
- Tofacitinib: A Review in Psoriatic Arthritis. (2019) pubmed
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (2024) pubmed
- Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. (2021) pubmed
- An evaluation of tofacitinib for the treatment of psoriatic arthritis. (2019) pubmed
- Tofacitinib for the treatment of psoriasis and psoriatic arthritis. (2018) pubmed
- Tofacitinib treatment for plaque psoriasis and psoriatic arthritis: A meta-analysis of randomised controlled trials. (2025) pubmed
- Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. (2021) pubmed